Document is current

Article History

Received: 25 January 2024

Accepted: 14 May 2024

First Online: 20 May 2024

Competing interests

: YY received grants or contracts from Daiichi-Sankyo, honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Torii, and Support for attending meetings from Bayer. JW received grants or contracts from Bayer, Chugai, Kyowa Kirin, Otsuka, Shionogi, Sumitomo, and Mitsubishi Tanabe, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Kyowa Kirin, Novo Nordisk Pharma, and Mitsubishi Tanabe. TY is board member of Japanese Society of Nephrology (unpaid). IN received grants or contracts from Bayer Yakuhin, Terumo, Chugai Pharmaceutical, Kyowa Kirin, Daiichi-Sankyo, Sumitomo Pharma, Amicus Thepeuticus, Terumo, Kaneka, Otsuka Pharmaceutical, Astellas Pharma, and Ono Pharmaceutical, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Sanofi, Otsuka Pharmaceutical, Bayer, and Kyowa Kirin. KY received grants or contracts from Kyowa-Kirin and Tanabe-Mitsubishi, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Kyowa-Kirin and Tanabe-Mitsubishi, Mochida, Astra-Zeneca, and Asteras. and Otsuka. MN received grants or contracts from Kyowa-Kirin, Tanabe-Mitsubishi, Chugai, Boehringer Ingelheim, Torii, Takeda, Daiichi-Sankyo, and JT, consulting fees from Kyowa-Kirin, and Tanabe-Mitsubishi, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Kyowa-Kirin, Tanabe-Mitsubishi, Bayer, Astellas, JT, and Astra Zeneca. NK received consulting fees from Kyowa-Kirin and NovoNordisk Pharma, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bayer Pharma, AstraZeneca, Ono Pharma, Novartis Phamak, Kyowa-Kirin, Boehringer Ingelheim Japan, Astellas Pharma, and Novo Nordisk Pharma, Participation on a Data Safety Monitoring Board or Advisory Board from Novo Nordisk Pharma and AstraZeneka, and board member of Japan Kidney Association. HO received grants or contracts from Kyowa Kirin, Torii Pharma, and Kissei Pharma, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astellas, Kyowa Kirin, Daiichi Sankyo, AstraZeneca, Bayer AG, Mitsubishi Tanabe Pharma, Torii Pharma, Ono Pharma, Boehringer Ingelheim International GmbH, Participation on a Data Safety Monitoring Board or Advisory Board from Boehringer Ingelheim International GmbH, Daiichi Sankyo, Elli Lily, Mitsubishi Tanabe Pharma, Kissei Pharma, and board member of Japanese Society of Nephrology (unpaid).